立方制药股东高美华减持30万股计划实施完毕，持股比例降至3.23%

Group 1 - The core point of the news is that Hefei Lifan Pharmaceutical Co., Ltd. has completed the share reduction plan by shareholder Gao Meihua, who reduced her holdings by 300,000 shares, accounting for 0.16% of the company's total share capital [1][2][3] Group 2 - The specific details of the reduction indicate that Gao Meihua executed the reduction through centralized bidding from July 28, 2025, to August 29, 2025, at an average price of 29.71 yuan per share, with a total of 300,000 shares reduced [2] - Prior to the reduction, Gao Meihua held 6,444,703 shares, representing 3.37% of the total share capital, which decreased to 6,144,703 shares, or 3.23%, after the reduction [2] - The shares reduced were sourced from shares held before the company's initial public offering and from capital reserve converted into share capital [2] Group 3 - The reduction complies with the relevant laws and regulations, including the Securities Law of the People's Republic of China and the Shenzhen Stock Exchange Listing Rules [3] - The implementation of this reduction plan does not lead to a change in the company's control or significantly impact its governance structure and future operations [3] - The company has indicated that the market should pay attention to its future development dynamics following the completion of this reduction plan [4]